HistoSonics announced today that it enrolled the first patients in a novel, prospective master protocol study evaluating histotripsy. BOOMBOX, a post-market master study, evaluates the real-world use of histotripsy to treat liver tumors. Minneapolis-based HistoSonics expects the study to provide important data for up to 5,000 patients treated across multi-disciplinary providers. HistoSonics said BOOMBOX represents […]
HistoSonics Inc.
HistoSonics closes $102M oversubscribed Series D
HistoSonics announced today that it completed an oversubscribed Series D financing round worth proceeds of $102 million. Alpha Wave Ventures led the round, while new investors Amzak Health and HealthQuest Capital participated. Johnson & Johnson Innovation – JJDC, Venture Investors, Lumira Ventures, Yonjin Venture, the State of Wisconsin Investment Board — all existing investors — […]
Histosonics plans expansion in Minnesota
According to a report from CCX Media last week, HistoSonics plans to expand its headquarters in Plymouth, Minnesota. HistoSonics develops a histotripsy treatment for liver tumor procedures. Last year, the FDA granted de novo authorization for its Edison system and novel histotripsy therapy platforms. The report says HistoSonics plans to nearly double the size of its headquarters […]
HistoSonics scores reimbursement win for sonic beam therapy
HistoSonics announced today that the Centers of Medicare & Medicaid Services (CMS) set a new payment rate for its tumor treatment. Minneapolis-based HistoSonics develops a histotripsy treatment for liver tumor procedures. Last month, the FDA granted de novo authorization for its Edison system and novel histotripsy therapy platforms. Edison, an image-guided sonic beam therapy system uses […]
FDA grants de novo nod to HistoSonics histotripsy system
HistoSonics announced today that the FDA granted de novo authorization for its Edison system and novel histotripsy therapy platforms. Edison, an image-guided sonic beam therapy system uses advanced imaging and proprietary sensing technology. It delivers non-invasive, personalized treatments with precision and control. The system received FDA investigational device exemption in February. In March, HistoSonics announced […]
HistoSonics announces first kidney tumor treatment with histotripsy
HistoSonics announced the treatment of the first kidney patient using the company’s histotripsy platform in the United Kingdom. Professor Tze Min Wah, senior consultant radiologist and clinical lead for the interventional oncology program at Leeds Teaching Hospitals NHS Trust, performed the procedure. It marks the initial treatment in HistoSonics’ sponsored “CAIN” trial. The Phase I […]
FDA approves HistoSonics IDE trial for sonic beam therapy that treats renal tumors
HistoSonics announced today that it received FDA approval for an investigational device exemption (IDE) trial of its Edison system. Minneapolis-based HistoSonics designed its Edison system to target and destroy targeted primary renal tumors. It achieves this in a non-invasive manner without the need for incisions or needles. Edison uses a novel sonic bean therapy called […]
J&J leads $85M raise for HistoSonics
HistoSonics announced today that it raised $85 million in a financing round led by Johnson & Johnson Innovation. Minneapolis-based HistoSonics develops a novel sonic beam therapy. This uses histotripsy, which mechanically destroys and liquified unwanted tissue and tumors at sub-cellular levels. It develops the non-invasive Edison platform that combines imaging with proprietary sensing technology to […]
HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
HistoSonics announced today that it agreed with GE Healthcare to use its ultrasound imaging to power novel sonic beam therapy. Minneapolis-based HistoSonics’ agreement formalizes ongoing efforts to use GE Healthcare’s Logiq E10 Series ultrasound imaging platform to power the real-time visualization features of HistoSonics’ sonic beam liver therapy platform. Under the agreement — and upon […]
HistoSonics announces $40m Series C
Non-invasive robotics platform and sonic beam therapy developer HistoSonics announced today that it closed a Series C-1 financing worth $40 million. Yonjin Venture led the oversubscribed funding round, while Varian Medical Systems, Johnson & Johnson Innovation, Venture Investors, Lumira Ventures, State of Wisconsin Investment Board and more participated as well, according to a news release. […]
HistoSonics touts first-in-human study results
HistoSonics said today that its non-invasive robotics platform and novel sonic beam cancer therapy successfully destroyed 11 tumors in eight patients during its first clinical trial. The results were presented this week at the 2019 Society of Interventional Oncology (SIO) Annual Meeting in Boston. The meeting also included preclinical presentations of what HistoSonics termed promising […]
